MX2013004137A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013004137A
MX2013004137A MX2013004137A MX2013004137A MX2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
indacaterol
ciclesonide
beta2
formoterol
Prior art date
Application number
MX2013004137A
Other languages
English (en)
Spanish (es)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2013004137A publication Critical patent/MX2013004137A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013004137A 2010-10-12 2011-07-25 Composicion farmaceutica. MX2013004137A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2847MU2010 2010-10-12
IN69MU2011 2011-01-10
IN106MU2011 2011-01-12
IN135MU2011 2011-01-14
IN143MU2011 2011-01-17
PCT/GB2011/001115 WO2012049444A1 (en) 2010-10-12 2011-07-25 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013004137A true MX2013004137A (es) 2013-07-29

Family

ID=44651863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004137A MX2013004137A (es) 2010-10-12 2011-07-25 Composicion farmaceutica.

Country Status (12)

Country Link
US (1) US10179139B2 (enExample)
EP (1) EP2627325A1 (enExample)
JP (2) JP2013542940A (enExample)
KR (2) KR20180028563A (enExample)
CN (2) CN103269694A (enExample)
AU (1) AU2011315315B2 (enExample)
BR (1) BR112013008974A2 (enExample)
CA (1) CA2814445A1 (enExample)
MX (1) MX2013004137A (enExample)
NZ (1) NZ609358A (enExample)
RU (1) RU2642624C2 (enExample)
WO (1) WO2012049444A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531056A (ja) 2010-07-16 2013-08-01 シプラ・リミテッド R(+)ブデソニド及び1以上の気管支拡張剤を含む医薬組成物
MX2013004137A (es) 2010-10-12 2013-07-29 Cipla Ltd Composicion farmaceutica.
CN103784420A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 马来酸茚达特罗液体制剂及其制备方法
EP3174522A1 (en) * 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物
KR20180042160A (ko) * 2015-05-18 2018-04-25 글렌마크 스페셜티 에스. 에이. 분무용 티오트로피움 흡입 용액
EP3515439B1 (en) * 2016-09-19 2021-12-15 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
GB2554090A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical compound
AU2017328908B2 (en) * 2016-09-19 2020-04-02 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2019146188A1 (ja) 2018-01-24 2019-08-01 ソニー株式会社 情報処理装置および情報処理方法
AU2019282562A1 (en) * 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
US20200163955A1 (en) * 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN115998680A (zh) * 2019-10-11 2023-04-25 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN116963715A (zh) * 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
EP4611733A1 (en) * 2022-11-03 2025-09-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US5879715A (en) 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
AU2001252588A1 (en) 2000-04-28 2001-11-12 Tanabe Seiyaku Co., Ltd. Method for preparing microsphere
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ATE396716T1 (de) 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
RU2327450C2 (ru) * 2002-08-29 2008-06-27 Сипла Лимитед Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
PT1572217E (pt) 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1635845A1 (en) * 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
SE527200C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
WO2005053851A1 (en) 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
US20060008498A1 (en) 2004-07-12 2006-01-12 Chen Tzer-Fen D Nano-particle production
DE102004056578A1 (de) 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid
WO2006073154A1 (ja) 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. 医薬組成物及びその製造方法
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US20100172994A1 (en) 2006-11-22 2010-07-08 University Of Florida Research Foundation, Inc. Nanoparticles for Protection of Cells from Oxidative Stress
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
TWI405590B (zh) 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
JP5109515B2 (ja) 2007-07-17 2012-12-26 株式会社ジェイテクト 摺動式トリポード形等速ジョイント
MX2010002781A (es) * 2007-09-12 2010-04-01 Glaxo Group Ltd Combinacion novedosa de angentes terapeuticos.
DE102007054885A1 (de) 2007-11-15 2009-05-20 Evonik Degussa Gmbh Verfahren zur Fraktionierung oxidischer Nanopartikel durch Querstrom-Membranfiltration
FR2929136B1 (fr) 2008-03-25 2011-11-11 Sprainnov Procede et tete de pulverisation, procede et tour associes pour fabriquer un produit pulverulent
CN102149437B (zh) * 2008-07-18 2017-02-15 普罗索尼克斯有限公司 用于提高氟替卡松颗粒结晶度的方法
CN101474191B (zh) 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
US8668901B2 (en) * 2009-02-04 2014-03-11 Activaero Gmbh Research & Development Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
NZ595902A (en) 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
MX2013004137A (es) 2010-10-12 2013-07-29 Cipla Ltd Composicion farmaceutica.

Also Published As

Publication number Publication date
EP2627325A1 (en) 2013-08-21
CA2814445A1 (en) 2012-04-19
AU2011315315A1 (en) 2013-05-09
CN103269694A (zh) 2013-08-28
NZ609358A (en) 2015-04-24
CN107998109A (zh) 2018-05-08
WO2012049444A1 (en) 2012-04-19
US20140147393A1 (en) 2014-05-29
BR112013008974A2 (pt) 2023-12-19
KR20140025308A (ko) 2014-03-04
RU2013119938A (ru) 2014-11-20
AU2011315315B2 (en) 2016-08-18
RU2642624C2 (ru) 2018-01-25
JP2017039746A (ja) 2017-02-23
KR20180028563A (ko) 2018-03-16
US10179139B2 (en) 2019-01-15
JP2013542940A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
BR112013008974A2 (pt) Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
HUS2000016I1 (hu) Drospirenont és fogamzásgátló kitet tartalmazó gyógyászati készítmény
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
ZA201307995B (en) Dose counters for inhalers, inhalers and shafts thereof
PT2688572T (pt) Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
EP3736282C0 (en) CELL-PERFORMING PEPTIDE, CONJUGATE THEREOF AND COMPOSITION WITH THE CONJUGATE
EP2771321A4 (en) HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
IL287905A (en) A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use
PL2552201T3 (pl) Pasożytobójcze kompozycje zawierające wiele środków aktywnych, sposoby i ich zastosowania
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
PL2575793T3 (pl) N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
ZA201508249B (en) A pharmaceutical composition containing budesonide and formoterol.
HK1212917A1 (zh) 含硫酸特布他林的剂型
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
WO2010150098A3 (en) Use of quingolide in the treatment of endometriosis, pain and cancer
IN2013MU03370A (enExample)
IL284980B1 (en) Heteroaryl-azacyclic-oxo-amide compound, pharmaceutical preparation and pharmaceutical preparation for use in the treatment
IL220422A (en) Pharmaceutical formulation in non-intestinal delivery, with delayed release, at low and low doses, for hormone therapy for menopause
MX2010006170A (es) Composicion farmaceutica para la limpieza del intestino.
WO2014013511A3 (en) Rufinamide solid dispersion
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative